Ali Erginay · enciclopedia

Publicaciones › Edema macular diabético y sus tratamientos

ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

ETOILE: Evidencia en el mundo real de 24 meses de ranibizumab 0,5 mg en pacientes con discapacidad visual debido a edema macular diabético

Año2021
FuenteClinical ophthalmology (Auckland, N.Z.)
Tipoarticle · Journal Article
Autores (10)Laurent Kodjikian, Amélie Lecleire-Collet, Corinne Dot, Marie-Laure Le Lez, Stéphanie Baillif, Ali Erginay, Eric Souied, Eric Fourmaux, Philippe Gain, Anne Ponthieux
Posición de Erginay6 de 10
Citas8 (OpenAlex)
EnlacesDOI 10.2147/opth.s313081 · PubMed 34113074 · OpenAlex · Texto completo en acceso abierto
LíneasEdema macular diabético y sus tratamientos Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo

En pocas palabras

Se estudió el efecto de la inyección de ranibizumab en pacientes con edema macular diabético. Los resultados mostraron una mejora en la agudeza visual después de 24 meses de tratamiento, a pesar de recibir menos inyecciones de las recomendadas. La mejora en la agudeza visual se relacionó con la completitud del tratamiento y la respuesta temprana al mismo.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

PURPOSE: To evaluate the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) in adults with decreased VA due to diabetic macular edema (DME). PATIENTS AND METHODS: Real-world prospective observational 24-month study. Ranibizumab-naïve patients (n=116) were enrolled, treated and followed up according to investigators' usual procedures. Outcomes included change from baseline to month 24 in best-corrected VA (BCVA; primary outcome), central retinal thickness (CRT), treatment exposure and safety. RESULTS: Overall, 62.9% of patients completed the study per protocol, 68.6% completed the induction phase (first three injections one month apart). On average, patients had 12.5 ophthalmologist visits and 5.74 injections in year 1, decreasing to 4.6 visits and 1.94 injections in year 2. Mean baseline BCVA was 58.4 letters, mean gain at M24 was +6.08 letters (95% CI: 2.95, 9.21). Gains were higher for patients who completed induction, and for patients who did not switch treatment. Mean CRT improved by 149.17 μm at M24. There were no new safety signals. BCVA variation of ≥6 letters by M3 was predictive of BCVA gains at M24 (p=0.007), as was hypertension medication at baseline (p=0.022). CONCLUSION: Real-world ranibizumab treatment improved VA in DME patients, despite fewer injections than recommended.